FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

研究用のみ。 完全な免責事項 →

スタックライブラリ

Circadian Reset

Sleep Optimizationintermediate

78

シナジー

78
Share
ペプチド

3

平均日用量mcg

5,400

レベル

intermediate

追加

May 17, 2026

概要

The Circadian Reset protocol addresses disrupted sleep-wake cycles through a multi-target approach that normalizes both the circadian oscillator and the downstream hormonal rhythms it controls. DSIP serves as the direct sleep promoter, facilitating delta-wave sleep onset and reducing the hyperarousal that prevents circadian entrainment. In shift workers and individuals with delayed sleep phase, DSIP helps establish a consistent sleep onset time by providing a reliable pharmacological "sleep gate" that the body can then entrain around. Epithalon''s role in this stack extends beyond its telomere-related effects to its documented influence on pineal gland function. Professor Khavinson''s research demonstrated that Epithalon normalizes melatonin production in elderly patients whose pineal glands had calcified and atrophied with age. By restoring melatonin synthesis to youthful levels, Epithalon helps re-establish the master circadian signal that synchronizes peripheral tissue clocks throughout the body. The 10-day evening administration cycle targets the pineal gland during its active phase (melatonin synthesis peaks at night), providing both immediate melatonin support and long-term pineal restoration. Morning Selank administration addresses the cortisol-awakening response and daytime alertness — the other half of circadian health. By reducing anxiety and normalizing stress hormones during the day, Selank prevents the evening cortisol elevation that is one of the most common causes of sleep-onset insomnia. Proper daytime alertness (supported by healthy cortisol rhythm) is as important to circadian health as nighttime sleep — the system requires contrast between active and rest phases. This stack is intermediate-level because it requires coordinated timing across three administration windows and includes the cyclical Epithalon component that requires scheduling awareness.

投与プロトコル

DSIP

nightly· subcutaneous

DSIPについて詳しく読む →

100 mcg

1回の投与あたり

Epithalon

nightly (10-day cycle)· subcutaneous

Epithalonについて詳しく読む →

5,000 mcg

1回の投与あたり

300 mcg

1回の投与あたり

目標と証拠

Circadian rhythmMelatonin regulationSleep qualityDaytime alertnessStress
証拠ランク:動物実験

警告

  • Epithalon and DSIP were removed from the FDA Category 2 list (April 2026) but remain pending PCAC review — not legal to compound yet. This combination targets both pineal function (Epithalon/DSIP) and daytime stress (Selank). Experimental protocol.

Comments

Sign in to join the discussion

注意: このスタックはコミュニティから提出され、研究用のみです。Peptide Contactsは提出されたスタックの安全性や効果性を確認していません。使用するペプチドプロトコル前に常に資格のある医療専門家に相談してください。